Home
Indication Area
NRT
Pharma
Partners
Team
Newsroom
CONTACT US
Home
Indication Area
NRT
Pharma
Partners
Team
Newsroom
contact us
Home
Indication Area
NRT
Pharma
Partners
Team
Newsroom
Home
Indication Area
NRT
Pharma
Partners
Team
Newsroom
CONTACT US
Have a Project in Mind? Say Hi!
+1 800 123 456 789
+1 800 123 654 987
Mon - Sun: 10am - 10pm
27 Division St, New York,
NY 10002, USA
grido@mail.com
Home
Grid 4 Columns
Grid 4 Columns
October 25, 2024
Forbes
BY
admin
This Startup Has A New Way To Quit Smoking. Will this be the one that works?
October 21, 2024
PR Neweswire
BY
admin
Qnovia, Inc. CEO Speaks at FDA and NIH Public Meeting to Encourage Innovation of Smoking Cessation Treatment Options
October 2, 2024
Drug Delivery Business
BY
admin
Qnovia wins FDA nod for nicotine inhaler as smoking cessation therapy
October 1, 2024
PR Neweswire
BY
admin
Qnovia, Inc. announces FDA clearance of IND application for lead asset RespiRx™ Nicotine Inhaler as a prescription smoking cessation therapy
April 9, 2024
Business Wire
BY
admin
Qnovia, Inc. Announces the Appointment of Four New Members to its Scientific Advisory Board
December 4, 2023
Medical Device Network
BY
admin
Qnovia’s inhaled smoking cessation therapy triumphs in first clinical study
November 30, 2023
Business Wire
BY
admin
Qnovia, Inc. announces positive results from first-in-human pharmacokinetic and safety study of lead asset QN-01, a prescription inhaled smoking cessation therapy
October 19, 2023
Business Wire
BY
admin
Qnovia Enters Collaboration with University of Virginia to Advance Inhaled Drug Candidates for Treating Infectious Diseases
LOAD MORE
#side-panel.side-panel {width: 500px;}#side-panel.side-panel .side-panel_sidebar {padding: 70px 0px 50px 60px;background-color: #FFFFFF;}
Qnovia